DERMATOLOGY REFERRAL FORM A-H

Phone (888) 370.1724 Fax (877) 645.7514 10004 S. 152nd St, Suite A, Omaha NE 68138



Address City State ZIP Phone SSN Prescriber Name Prescriber NPI Insurance Plan Plan ID # Fax Email Diagnosis/Clinical Information PLEASE FAX CLINICAL AND LAB INFORMATION Diagnosis: L20 Atopic Dermatitis L40.0 Psoriasis vulgaris/Plaque psoriasis/Nummular psoriasis L40.8 Other psoriasis L40.9 Psoriasis, unspecified L40.5 Psoriatic arthritis L73.2 Hidradenitis Suppurativa Other: Date of diagnosis or years with the disease: Active TB is ruled out: Yes No Date of negative TB test: / Concomitant medications: Previous treatment regimens with dates and reason for discontinuation: Prescription Information	Patient Information PLEASE			FAX INSURANCE CARD (FRONT AND BACK)			Prescriber Information					
Covering the control of the control	Last Name First Name		DOB			Practice/Facility Name						
Process	Address						Address					
Available Lates Allergy No	City State		State		ZIP		City State		ZIP			
See Maile Female Weight Page Pag	Phone		•	SSN			Prescriber Name	•				
Paul D # Paul D # First Paul D # First Paul D # First	Allergies			Latex Allergy Yes No			Prescriber NPI					
Diagnosis / Clinical Information Diagnosis L20	Sex Male Female Weight (kg)			Height (ft,in)			Nurse/Key Contact Phone/Pager					
Diagnosis: L20Atopic Dermattis L40.0 Psoriasis vulgaris/Plaque psoriasis (Nummular psoriasis L40.8 Other psoriasis L40.5 Psoriasis, unspecified L40.5 Psoriasis unspecified L40.5 Psoriasis unspecified L40.5 Psoriasis unspecified cut 'es No Date of negative TB test:	Insurance Plan			Plan ID #			Fax	Email				
Diagnosis: L20Atopic Dermattis L40.0 Psoriasis vulgaris/Plaque psoriasis (Nummular psoriasis L40.8 Other psoriasis L40.5 Psoriasis, unspecified L40.5 Psoriasis unspecified L40.5 Psoriasis unspecified L40.5 Psoriasis unspecified cut 'es No Date of negative TB test:	Diagnosis/Clinical Information PLEASE FAX CLINICAL AND LAB INFORMATION											
Active TB is ruled out: Yes No Date of negative TB test:												
Prescription Information MEDICATION DOSE/STRENGTH/DIRECTIONS FOR USE QTY REFILLS Cimzia® Starter dose: Inject 400mg SC at weeks 0, 2 and 4 6 x 200mg/ml 0 Maintenance dose: Inject 200mg SC every 2 weeks Maintenance dose: Inject 400mg SC on week 4 x weeks 0, 1, 2 and 3 8 x 150mg/ml 0 Starter dose: Inject 150mg SC once weekly at weeks 0, 1, 2 and 3 8 x 150mg/ml 0 Maintenance dose: Inject 150mg SC once weekly at weeks 0, 1, 2 and 3 8 x 150mg/ml 0 Maintenance dose: Inject 150mg SC once weekly at weeks 0, 1, 2 and 3 8 x 150mg/ml 0 Maintenance dose: Inject 150mg SC on week 4 and every 4 weeks thereafter 1x 150mg/ml Maintenance dose: Inject 150mg SC on week 4 and every 4 weeks thereafter 2x 150mg/ml 0 Dupleent® prs	Active TB is ruled out:	Yes		Date of negati	ive TB test:/	/						
DOSE/STRENGTH/DIRECTIONS FOR USE QTY REFILLS			dates and rea	son for discontinua	tion:							
Starter dose: Inject 400mg SC at weeks 0, 2 and 4	Prescription Ir	nformat	ion									
Starter dose: Inject 400mg SC at weeks 0, 2 and 4	MEDICATION	MEDICATION			DOSE/STRENGTH/DIRECTIONS FOR USE					QTY		
Maintenance dose: Inject 200mg SC every 2 weeks Sensoready Pen PFS Sensoready Pen PFS Sensoready Pen PFS Sensoready Pen PFS Maintenance dose: Inject 300mg SC once weekly at weeks 0, 1, 2 and 3 Starter dose: Inject 150mg SC once weekly at weeks 0, 1, 2 and 3 Starter dose: Inject 300mg SC once weekly at weeks 0, 1, 2 and 3 Starter dose: Inject 300mg SC on week 4 and every 4 weeks thereafter Maintenance dose: Inject 500mg SC on week 4 and every 4 weeks thereafter PFS Starter dose: Inject 500mg SC on day 1, followed by 300mg SC at day 15 and every 2 weeks thereafter Maintenance dose: Inject 500mg SC on day 1, followed by 300mg SC at day 15 and every 2 weeks thereafter Maintenance dose: Inject 50mg SC twice a week (72-96 hours apart) for 3 months 8 x 50mg/ml 2 x 250mg/zml Phaterial Mini Enbrel® Pedatric 24yo Pedatric 24yo Pedatric 24yo Pers FFS Inject	Cimzia®	PFS		Starter dose: Inject 400mg SC at weeks 0, 2 and 4					6 x 200mg/ml		0	
Sensoready Pen PFS								2 x 200mg/ml				
Maintenance dose: Inject 150mg SC on week 4 and every 4 weeks thereafter	Cosentyx®			Starter dose: Inject 150mg SC once weekly at weeks 0, 1, 2 and 3					4 x 15	i0mg/ml	0	
Maintenance dose: Inject 300mg SC on week 4 and every 4 weeks thereafter 2 x 150mg/ml			eady Pen						-	8 x 150mg/ml		
Starter dose: Inject 600mg SC on day 1, followed by 300mg SC at day 15 and every 2 weeks thereafter Maintenance dose: Inject 300mg SC every 2 weeks 2 x 300mg/2ml												
PFS every 2 weeks thereafter	Dunivant®								2 X 13	oung/iii		
Enbrel® Adult SureClick Autoinjector PFS Enbrel® Mini Maintenance dose: Inject 50mg SC twice a week (72-96 hours apart) for 3 months 8 x 50mg/ml 2	Биріхенте	PFS							4 x 300mg/2ml (0	
Adult PFS Enbrel® Mini Maintenance dose: Inject 50mg SC every week 4 x 50mg/ml				Maintenance dose: Inject 300mg SC every 2 weeks					2 x 300mg/2ml			
Enbrel® Pediatric ≥4yo Weightkg									_		2	
Pediatric ≥4yo Weightkg			LIIDI EI® IVIIIII	Maintenance dose: Inject 50mg SC every week					4 x 50mg/ml			
Humira® Pens Pens Plaque psoriasis (starter dose): Inject 160mg SC on day 1, then 40mg on day 15 then 40mg/0.8ml on then 40mg SC on day 29 and every week thereafter Humira® Pens Pens Pens Pens Induction Dose (Citrate-free) Hidradenitis Suppurativa (starter dose): Inject 80mg SC day 1, then 40mg SC on day 15 then 40mg/0.8ml on day 29 and every week thereafter Pens Pens Pens Pens Pens Pens Pens Pens				Injectmg (0.8mg/kg) SC every week (<63 kg)					x 25mg			
PFS	Weightkg			Inject 50mg SC every week (≥63kg)				4 x 50mg				
Humira® Induction Dose (Citrate-Free) Pens PFS Plaque psoriasis (starter dose): Inject 80mg SC day 1, then 40mg SC on day 8, then 40mg SC on day 8, then 40mg SC on day 1, 80mg/0.8mL, 2 x 40mg/0.4mL Hidradenitis Suppurativa (starter dose): Inject 160mg SC on day 1, 80mg on day 15, then 40mg SC on day 29 and every week thereafter Humira® MAINTENANCE DOSE MAINTENANCE DOSE 40mg/0.8mL Pen 40mg/0.4mL Pen (Citrate-free) 40mg/0.4mL PFS (Citrate-free) 40mg/0.4mL PFS (Citrate-free) Other:	Humira®			every 2 weeks Hidradenitis Suppurativa (starter dose): Inject 160mg SC on day 1, then 80mg on day 15					1		0	
Hidradenitis Suppurativa (starter dose): Inject 160mg SC on day 1, 80mg on day 15, then 40mg SC on day 29 and every week thereafter Humira®	Induction Dose			Plaque psoriasis (starter dose): Inject 80mg SC day 1, then 40mg SC on day 8, then 40				40mg	80mg/0.8mL, 0		0	
MAINTENANCE DOSE 40mg/0.8mL PFS 40mg/0.4mL Pen (Citrate-free) 40mg/0.4mL PFS (Citrate-free) 40m	(Citrate-Free)										0	
DOSE 40mg/0.4mL Pen (Citrate-free) 40mg/0.4mL PFS (Citrate-free) Other: Hidradenitis Suppurativa (maintenance dose) 40mg SC injection EVERY week #4 # Other: were product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitution:	Humira®	MAINTENANCE 40mg/0.8mL PFS 40mg/0.4mL Pen (6		Hidradenitis Suppurativa (maintenance dose) 40mg SC injection EVERY week					#2			
order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitution:									#4			
									#		<u> </u>	
											TED	

PRODUCT SUBSTITUTION PERMITTED/Brand exchange permitted (date) DISPENSE AS WRITTEN/Do Not Substitute Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.